What does tumor mutational burden mean for Waldenstrom Macroglobulinemia immunotherapy

Tumor Mutational Burden (TMB) and Waldenstrom Macroglobulinemia: What You Should Know

I appreciate this question because it highlights an important gap in how we think about immunotherapy for different cancers. Let me explain what TMB means and why it's less relevant for Waldenstrom macroglobulinemia (WM) than it might be for other cancers.

What Is Tumor Mutational Burden?

Tumor mutational burden (TMB) is a count of how many mutations (changes in DNA) exist in your cancer cells. Think of it like this: when cells divide, they sometimes make copying errors in their DNA—like typos in a document. Most cells fix these errors, but cancer cells accumulate many of them.

According to the CancerPatientLab webinar on immunotherapy biomarkers, TMB is "a more generalized statistic of how many changes are in the DNA of cancer cells." The theory is straightforward: tumors with more mutations are more likely to be recognized as "foreign" by your immune system, making them better targets for immunotherapy drugs.

Why TMB Matters for Some Cancers (But Not WM)

The FDA approved TMB as a tissue-agnostic biomarker in 2020, meaning it can apply across many cancer types. For cancers like melanoma and lung cancer with high mutation rates, TMB has proven useful in predicting immunotherapy response.

However, Waldenstrom macroglobulinemia is fundamentally different.

TMB and Waldenstrom: The Critical Difference

Here's what's important to understand: WM is a lymphoid cancer (cancer of immune cells), not a solid tumor. This distinction matters enormously.

According to the NCCN Guidelines for Patients on Waldenstrom Macroglobulinemia, the primary treatments for WM are:

• Targeted therapies (like BTK inhibitors: ibrutinib and zanubrutinib)
• Chemotherapy (like bendamustine combined with rituximab)
• Monoclonal antibodies (like rituximab, which targets the CD20 protein on WM cells)

Notice what's not listed as a standard primary therapy for WM? Immune checkpoint inhibitors (the drugs that work by "removing the brakes" from the immune system—the type of immunotherapy where TMB becomes predictive).

The Clinical Reality for WM

WM cells are already immune cells that have gone wrong. The treatment strategy is different from solid tumors:

• Rituximab works by acting as a "beacon" to help your immune system find and attack WM cells that have the CD20 protein
• BTK inhibitors block a specific protein (BTK) that helps WM cells survive and multiply
• These approaches target the cancer cells directly or their specific vulnerabilities—not by "waking up" a dormant immune system

This is why TMB testing is not part of standard WM evaluation, according to NCCN Guidelines.

What This Means for Your Care

If you have Waldenstrom macroglobulinemia:

1. TMB testing is not typically recommended as part of standard WM workup

2. Your treatment decisions will be based on different factors, including:

   • Your IgM level (the abnormal protein your WM cells produce)
   • Whether you have symptoms (hyperviscosity syndrome, anemia, etc.)
   • Your bone marrow involvement
   • Your response to initial therapy

3. Questions to ask your oncologist:

   • "What biomarkers or test results will guide my treatment decisions?"
   • "Are there any genetic mutations in my WM cells that would affect treatment choices?"
   • "Will my treatment be based on targeted therapy, chemotherapy, or a combination?"
   • "How will we measure whether my treatment is working?"
   • "Are there any clinical trials available for my specific WM situation?"

The Bottom Line

While tumor mutational burden is an important predictor for immunotherapy response in many cancers, it's not the relevant biomarker for standard Waldenstrom macroglobulinemia treatment. Your care team will focus on other factors—particularly your IgM levels, symptoms, and how your WM cells respond to targeted therapies and rituximab-based treatments.

According to the NCCN Guidelines, the goal of WM treatment is to "relieve your symptoms and reduce the risk of damage to your organs"—and that's best achieved through the targeted and chemotherapy approaches that have proven effective for this specific disease.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.